Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Major Shareholder Sells 33,273 Shares of Stock

NewAmsterdam Pharma (NASDAQ:NAMS) major shareholder Nap B.V. Forgrowth sold 33,273 shares of the company’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $25.08, for a total value of $834,486.84. Following the transaction, the insider now directly owns 11,778,760 shares in the company, valued at $295,411,300.80. This trade represents a 0.28 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Nap B.V. Forgrowth also recently made the following trade(s):

• On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS opened at $20.00 on Friday. The stock has a 50-day moving average price of $18.98 and a two-hundred day moving average price of $18.63. NewAmsterdam Pharma has a 1 year low of $8.90 and a 1 year high of $26.35.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Piper Sandler reaffirmed an “overweight” rating and set a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Royal Bank of Canada restated an “outperform” rating and set a $31.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research report on Thursday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Buy” and an average price target of $33.80.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of NAMS. Geode Capital Management LLC raised its position in NewAmsterdam Pharma by 1.6% in the 3rd quarter. Geode Capital Management LLC now owns 86,322 shares of the company’s stock valued at $1,433,000 after buying an additional 1,399 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in shares of NewAmsterdam Pharma during the 2nd quarter worth approximately $38,000. Quarry LP raised its holdings in shares of NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock valued at $108,000 after purchasing an additional 6,247 shares during the last quarter. Barclays PLC lifted its position in shares of NewAmsterdam Pharma by 1,813.4% in the third quarter. Barclays PLC now owns 7,596 shares of the company’s stock worth $126,000 after purchasing an additional 7,199 shares in the last quarter. Finally, Bellevue Group AG acquired a new position in NewAmsterdam Pharma during the third quarter worth $128,000. 89.89% of the stock is owned by institutional investors and hedge funds.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.